262 related articles for article (PubMed ID: 36201122)
1. Osteoclast Recycling and the Rebound Phenomenon Following Denosumab Discontinuation.
Kim AS; Girgis CM; McDonald MM
Curr Osteoporos Rep; 2022 Dec; 20(6):505-515. PubMed ID: 36201122
[TBL] [Abstract][Full Text] [Related]
2. Temporal patterns of osteoclast formation and activity following withdrawal of RANKL inhibition.
Kim AS; Taylor VE; Castro-Martinez A; Dhakal S; Zamerli A; Mohanty S; Xiao Y; Simic MK; Wen J; Chai R; Croucher PI; Center JR; Girgis CM; McDonald MM
J Bone Miner Res; 2024 May; 39(4):484-497. PubMed ID: 38477789
[TBL] [Abstract][Full Text] [Related]
3. Reduced osteoprotegerin expression by osteocytes may contribute to rebound resorption after denosumab discontinuation.
Fu Q; Bustamante-Gomez NC; Reyes-Pardo H; Gubrij I; Escalona-Vargas D; Thostenson JD; Palmieri M; Goellner JJ; Nookaew I; Barnes CL; Stambough JB; Ambrogini E; O'Brien CA
JCI Insight; 2023 Sep; 8(18):. PubMed ID: 37581932
[TBL] [Abstract][Full Text] [Related]
4. [Anti-RANKL antibody].
Omiya T; Tanaka S
Nihon Rinsho; 2015 Oct; 73(10):1690-5. PubMed ID: 26529931
[TBL] [Abstract][Full Text] [Related]
5. Changes in RANKL and TRAcP 5b after discontinuation of denosumab suggest RANKL mediated formation of osteoclasts results in the increased bone resorption.
Sølling AS; Harsløf T; Jørgensen NR; Langdahl B
Osteoporos Int; 2023 Mar; 34(3):599-605. PubMed ID: 36543965
[TBL] [Abstract][Full Text] [Related]
6. In Vitro Study of the Effects of Denosumab on Giant Cell Tumor of Bone: Comparison with Zoledronic Acid.
Shibuya I; Takami M; Miyamoto A; Karakawa A; Dezawa A; Nakamura S; Kamijo R
Pathol Oncol Res; 2019 Jan; 25(1):409-419. PubMed ID: 29159783
[TBL] [Abstract][Full Text] [Related]
7. Osteoclasts recycle via osteomorphs during RANKL-stimulated bone resorption.
McDonald MM; Khoo WH; Ng PY; Xiao Y; Zamerli J; Thatcher P; Kyaw W; Pathmanandavel K; Grootveld AK; Moran I; Butt D; Nguyen A; Corr A; Warren S; Biro M; Butterfield NC; Guilfoyle SE; Komla-Ebri D; Dack MRG; Dewhurst HF; Logan JG; Li Y; Mohanty ST; Byrne N; Terry RL; Simic MK; Chai R; Quinn JMW; Youlten SE; Pettitt JA; Abi-Hanna D; Jain R; Weninger W; Lundberg M; Sun S; Ebetino FH; Timpson P; Lee WM; Baldock PA; Rogers MJ; Brink R; Williams GR; Bassett JHD; Kemp JP; Pavlos NJ; Croucher PI; Phan TG
Cell; 2021 Mar; 184(5):1330-1347.e13. PubMed ID: 33636130
[TBL] [Abstract][Full Text] [Related]
8. RANKL as a target for the treatment of osteoporosis.
Matsumoto T; Endo I
J Bone Miner Metab; 2021 Jan; 39(1):91-105. PubMed ID: 33057808
[TBL] [Abstract][Full Text] [Related]
9. Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data.
Dempster DW; Lambing CL; Kostenuik PJ; Grauer A
Clin Ther; 2012 Mar; 34(3):521-36. PubMed ID: 22440513
[TBL] [Abstract][Full Text] [Related]
10. Multiple idiopathic external cervical root resorption in patient treated continuously with denosumab: a case report.
Mikušková K; Vaňuga P; Adamicová K; Statelová D; Janíčková M; Malachovský I; Siebert T
BMC Oral Health; 2022 Apr; 22(1):129. PubMed ID: 35428235
[TBL] [Abstract][Full Text] [Related]
11. [The mechanism of anti-RANKL antibody in the treatment of metabolic bone diseases including osteoporosis - possible applications of anti-RANKL antibody to the treatment of cancer patients].
Yasuda H
Nihon Yakurigaku Zasshi; 2019; 153(1):11-15. PubMed ID: 30643086
[TBL] [Abstract][Full Text] [Related]
12. [The role of rank-ligand inhibition in the treatment of postmenopausal osteoporosis].
Varenna M; Gatti D
Reumatismo; 2010; 62(3):163-71. PubMed ID: 21052563
[TBL] [Abstract][Full Text] [Related]
13. Anti-RANKL antibody was approved for the treatment of osteoporosis in Japan.
Yasuda H
Nihon Rinsho Meneki Gakkai Kaishi; 2013; 36(4):209-16. PubMed ID: 23994799
[TBL] [Abstract][Full Text] [Related]
14. Elevated Bone Hardness Under Denosumab Treatment, With Persisting Lower Osteocyte Viability During Discontinuation.
Jähn-Rickert K; Wölfel EM; Jobke B; Riedel C; Hellmich M; Werner M; McDonald MM; Busse B
Front Endocrinol (Lausanne); 2020; 11():250. PubMed ID: 32499755
[TBL] [Abstract][Full Text] [Related]
15. Changes in Dkk-1, sclerostin, and RANKL serum levels following discontinuation of long-term denosumab treatment in postmenopausal women.
Fassio A; Adami G; Benini C; Vantaggiato E; Saag KG; Giollo A; Lippolis I; Viapiana O; Idolazzi L; Orsolini G; Rossini M; Gatti D
Bone; 2019 Jun; 123():191-195. PubMed ID: 30910600
[TBL] [Abstract][Full Text] [Related]
16. Ebselen Is a Potential Anti-Osteoporosis Agent by Suppressing Receptor Activator of Nuclear Factor Kappa-B Ligand-Induced Osteoclast Differentiation In vitro and Lipopolysaccharide-Induced Inflammatory Bone Destruction In vivo.
Baek JM; Kim JY; Yoon KH; Oh J; Lee MS
Int J Biol Sci; 2016; 12(5):478-88. PubMed ID: 27019631
[TBL] [Abstract][Full Text] [Related]
17. A review of denosumab for the treatment of osteoporosis.
Miyazaki T; Tokimura F; Tanaka S
Patient Prefer Adherence; 2014; 8():463-71. PubMed ID: 24748775
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of RANK/RANKL signal transduction pathway: a promising approach for osteoporosis treatment.
Bai YD; Yang FS; Xuan K; Bai YX; Wu BL
Med Hypotheses; 2008 Aug; 71(2):256-8. PubMed ID: 18445511
[TBL] [Abstract][Full Text] [Related]
19. Denosumab for the treatment of osteoporosis.
Iqbal J; Sun L; Zaidi M
Curr Osteoporos Rep; 2010 Dec; 8(4):163-7. PubMed ID: 20857349
[TBL] [Abstract][Full Text] [Related]
20. [Multiple Vertebral Fractures after Denosumab Discontinuation: How to Avoid Them?].
Lamy O; Gonzalez Rodriguez E; Stoll D; Aubry-Rozier B; Livio F
Praxis (Bern 1994); 2018 Jun; 107(12):649-654. PubMed ID: 29871576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
